Biohaven Pharmaceutical Holding Co Ltd. 即将在欧洲肿瘤内科学会(ESMO)大会上展示其创新药物BHV-1530的最新临床试验结果。BHV-1530是一款靶向FGFR3的抗体偶联药物(ADC),其独特之处在于搭载了公司专有的拓扑异构酶I(Topoix)载荷技术。
Biohaven Pharmaceutical Holding Co Ltd. 即将在欧洲肿瘤内科学会(ESMO)大会上展示其创新药物BHV-1530的最新临床试验结果。BHV-1530是一款靶向FGFR3的抗体偶联药物(ADC),其独特之处在于搭载了公司专有的拓扑异构酶I(Topoix)载荷技术。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.